News By Tag
News By Place
NAPSR news:Abbvie and Infinity Pharma Collaborate to Develop and Commercialize Duvelisib in Oncology
Biotech giant Abbvie's collaborative deal with Infinity Pharmaceuticals to develop and market duvelisib is worth approximately $800 million.
In accordance with the agreement, Infinity is set to receive an upfront payment of $275 million and is eligible to receive up to$530 million in additional payments for the achievement of development, regulatory and commercial milestones, including up to $405 million for the achievement of milestones through the first commercial sale of duvelisib. Upon regulatory approval, Infinity and Abbvie will commercialize duvelisib in the United States thus sharing potential profits or losses.
"We believe that duvelisib is a very promising investigational treatment based on clinical data showing activity in a broad range of blood cancers," said Michael Severino, M.D., AbbVie executive vice president and chief scientific officer. "The addition of duvelisib will complement AbbVie's emerging oncology pipeline and expand our research into combination therapies to generate improved outcomes for cancer patients. We look forward to working with Infinity to bring duvelisib to patients worldwide."
"This collaboration is an important step toward fulfilling Infinity's objective of bringing better treatments to patients and further advances our goal of building a sustainable, fully integrated biotechnology company," stated Adelene Q. Perkins, chair, president and chief executive officer at Infinity. "AbbVie will be a wonderful partner for Infinity, bringing all of the expertise and scale of a successful, well established company, together with the energy, drive, innovation, and nimbleness of a young organization. We look forward to advancing duvelisib through monotherapy studies designed to enable registration and in furthering our shared longer-term vision of combining duvelisib with both current standards of care and novel, targeted therapies."
Both companies will share responsibility for future development which includes plans to launch multiple Phase 2 and Phase 3 studies of duvelisib in hematologic malignancies over the next several years.The continuous research and development of duvelisib will certainly be an effective asset to both companies' oncology pipeline. If successful, pending regulatory approval, this treatment will join other effective therapies currently on the market. This will without a doubt bolster the need for both certified and qualified individuals to promote the company’s diversified product portfolio. When industry leaders look for new candidates for sales/marketing positions, they look toward individuals that are industry trained. Companies are looking for people that have the background to sell their product both proficiently and efficiently.
CANDIDATES WHO WANT TO BREAK INTO PHARMACEUTICAL SALES!
The CNPR is a federally trademarked certification you can earn by demonstrating the necessary knowledge in pharmacology, medical terminology, physiology, and regulations for selling pharmaceuticals. The CNPR examination is dedicated to increasing the professional level of NAPSR members and to developing meaningful and ethical standards fully accepted by both its members and members of the pharmaceutical community.
The CNPR® Program represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Pharmaceutical sales candidates who have this training will differentiate themselves from other individuals looking for open positions. Upon successful completion of the training each student will receive the Certification Mark of the CNPR®. CNPR® graduates should immediately utilize the NAPSRx® Career Center to apply for pharmaceutical sales positions.
Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives(